These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

101 related items for PubMed ID: 7198201

  • 1. Progressive supranuclear palsy: functional analysis of the response to methysergide and antiparkinsonian agents.
    Rafal RD, Grimm RJ.
    Neurology; 1981 Dec; 31(12):1507-18. PubMed ID: 7198201
    [Abstract] [Full Text] [Related]

  • 2. [Therapy of progressive supranuclear paralysis. Effect of methysergide and bromocriptine on various psychoneurologic and motor functions].
    Giménez-Roldán S, de Andrés C, Salinero E.
    Rev Clin Esp; 1979 Apr 15; 153(1):21-7. PubMed ID: 461893
    [No Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7. [Progressive supranuclear palsy. Diagnostic problems].
    Kristensen MO.
    Ugeskr Laeger; 1985 Sep 23; 147(39):3074-5. PubMed ID: 4071761
    [No Abstract] [Full Text] [Related]

  • 8. The treatment of progressive supranuclear palsy with L-dopa.
    Donaldson IM.
    Aust N Z J Med; 1973 Aug 23; 3(4):413-6. PubMed ID: 4519129
    [No Abstract] [Full Text] [Related]

  • 9. Controlled trial of pergolide mesylate in Parkinson's disease and progressive supranuclear palsy.
    Jankovic J.
    Neurology; 1983 Apr 23; 33(4):505-7. PubMed ID: 6339985
    [Abstract] [Full Text] [Related]

  • 10. Progressive supranuclear palsy (report of 4 cases with particular reference to blepharospasm and levodopa therapy).
    Singh S, Smith BH, Lal A.
    Neurol India; 1974 Jun 23; 22(2):65-71. PubMed ID: 4437701
    [No Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12. L-dopa for progressive supranuclear palsy.
    Jenkins R.
    Lancet; 1969 Oct 04; 2(7623):742. PubMed ID: 4186183
    [No Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14. [Progressive supranuclear paralysis. Critical review, with a note on verbal expression disorders and action of L-dopa].
    Giménez-Roldán S, Esteban A.
    Arch Neurobiol (Madr); 1972 Oct 04; 35(1):41-60. PubMed ID: 5060240
    [No Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17. Progression of gait, speech and swallowing deficits in progressive supranuclear palsy.
    Goetz CG, Leurgans S, Lang AE, Litvan I.
    Neurology; 2003 Mar 25; 60(6):917-22. PubMed ID: 12654953
    [Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19. [Frontal syndrome of progressive supranuclear palsy].
    Cambier J, Masson M, Viader F, Limodin J, Strube A.
    Rev Neurol (Paris); 1985 Mar 25; 141(8-9):528-36. PubMed ID: 4089415
    [Abstract] [Full Text] [Related]

  • 20. The use of lisuride, a potent dopamine and serotonin agonist, in the treatment of progressive supranuclear palsy.
    Neophytides A, Lieberman AN, Goldstein M, Gopinathan G, Leibowitz M, Bock J, Walker R.
    J Neurol Neurosurg Psychiatry; 1982 Mar 25; 45(3):261-3. PubMed ID: 7086448
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 6.